This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
zika virus | 1317 |
zikv infection | 620 |
study design | 539 |
case studies | 484 |
background case | 481 |
design method | 387 |
results finding | 375 |
virus infection | 372 |
vero cells | 233 |
blood bank | 188 |
viral rna | 187 |
infected cells | 177 |
red blood | 175 |
whole blood | 151 |
pregnant women | 144 |
results findings | 144 |
design methods | 138 |
blood donors | 135 |
west nile | 121 |
blood center | 120 |
natal rgn | 120 |
dengue virus | 118 |
zikv natal | 118 |
nile virus | 106 |
blood cells | 103 |
natural products | 102 |
immune response | 102 |
blood products | 100 |
zikv strains | 99 |
public health | 95 |
blood cell | 94 |
zikv rna | 94 |
red cell | 93 |
blood group | 87 |
retinoic acid | 85 |
antiviral activity | 85 |
performed using | 85 |
spinal cord | 83 |
mg dl | 81 |
united states | 80 |
flow cytometry | 79 |
blood components | 79 |
viral replication | 79 |
room temperature | 78 |
sexual transmission | 77 |
rbc units | 76 |
transfusion medicine | 73 |
statistically significant | 72 |
zikv replication | 71 |
type i | 71 |
virus replication | 70 |
blood transfusion | 69 |
mouse model | 68 |
yellow fever | 68 |
body weight | 67 |
previously described | 67 |
blood product | 67 |
neutralizing antibodies | 66 |
transfusion service | 65 |
french polynesia | 65 |
represented sequences | 64 |
viral load | 63 |
significantly higher | 62 |
zikv ns | 62 |
stem cell | 61 |
neutralizing antibody | 61 |
cell culture | 61 |
viral infections | 59 |
days post | 59 |
nervous system | 58 |
significant difference | 58 |
thermo fisher | 57 |
blood donor | 57 |
amino acid | 57 |
medical center | 57 |
viral genome | 56 |
ebola virus | 56 |
blood donation | 55 |
rhce ce | 54 |
cord uid | 54 |
transfusion reactions | 54 |
antibody screen | 54 |
doc id | 54 |
viral infection | 52 |
rgn srips | 51 |
bone marrow | 51 |
immune responses | 51 |
respiratory syndrome | 50 |
weight loss | 50 |
innate immune | 50 |
spectrum antiviral | 50 |
host cell | 50 |
risk factors | 49 |
pediatr radiol | 49 |
cell lines | 49 |
fisher scientific | 49 |
previously reported | 48 |
platelet count | 48 |
viral loads | 47 |
pfu ml | 47 |
chikungunya virus | 47 |
sg assembly | 47 |
central nervous | 47 |
red cells | 46 |
ag mice | 46 |
center background | 46 |
blood samples | 46 |
time points | 45 |
massive transfusion | 45 |
clinical trials | 44 |
endoplasmic reticulum | 44 |
congenital zika | 44 |
motor deficits | 44 |
positive samples | 44 |
pregnant mice | 43 |
stem cells | 43 |
health organization | 43 |
peripheral blood | 43 |
nucleic acid | 43 |
blood donations | 43 |
abo rh | 43 |
zikv challenge | 43 |
rna copies | 43 |
influenza virus | 43 |
testicular tissue | 42 |
quality control | 42 |
way anova | 42 |
mr imaging | 42 |
blood centers | 42 |
analyzed using | 42 |
antibody titers | 41 |
infectious virus | 41 |
japanese encephalitis | 41 |
animal models | 41 |
encephalitis virus | 41 |
reverse transcription | 41 |
zikv strain | 41 |
plaque assay | 41 |
nk cells | 41 |
virus entry | 40 |
three times | 40 |
aedes aegypti | 40 |
mg kg | 40 |
pathogen reduction | 40 |
mean age | 40 |
cell death | 40 |
ng ml | 40 |
magnetic resonance | 40 |
world health | 40 |
clinically significant | 40 |
vaccine development | 39 |
viral proteins | 39 |
pediatric patients | 39 |
infectious diseases | 39 |
host cells | 39 |
er stress | 39 |
viral diseases | 38 |
blood loss | 38 |
antibody response | 38 |
infected mice | 38 |
red cross | 38 |
blood type | 38 |
rbc transfusion | 38 |
virus disease | 38 |
zikv ediii | 37 |
may also | 37 |
significant differences | 37 |
cell line | 37 |
respiratory syncytial | 37 |
virus outbreak | 36 |
apheresis platelets | 36 |
syncytial virus | 36 |
blood services | 36 |
year old | 36 |
cdna clone | 36 |
zikv infections | 35 |
fever virus | 35 |
puerto rico | 35 |
fetal brain | 35 |
syndrome coronavirus | 35 |
adverse events | 35 |
blood volume | 35 |
blood supply | 35 |
endothelial cells | 35 |
treated cells | 34 |
statistical analysis | 34 |
well plates | 34 |
patient care | 34 |
significantly different | 34 |
life cycle | 33 |
monoclonal antibodies | 33 |
sickle cell | 33 |
zika syndrome | 33 |
statistical significance | 33 |
viral protein | 33 |
within hours | 33 |
host immune | 33 |
i interferon | 33 |
rna viruses | 33 |
copies ml | 32 |
retrospective study | 32 |
infectious disease | 32 |
cell viability | 32 |
viral titers | 32 |
virus infections | 32 |
computed tomography | 32 |
rna synthesis | 32 |
white matter | 31 |
vertical transmission | 31 |
mutant virus | 31 |
time pcr | 31 |
western blotting | 31 |
natural product | 31 |
medical record | 31 |
negative control | 31 |
zikv proteins | 30 |
patient blood | 30 |
treated mice | 30 |
south america | 30 |
dnk cells | 30 |
results suggest | 30 |
results showed | 29 |
protein expression | 29 |
ic values | 29 |
virus associated | 29 |
independent experiments | 29 |
transfusion vol | 29 |
unique teaching | 29 |
imaging findings | 29 |
viral particles | 29 |
teaching points | 29 |
cd cells | 29 |
transfusion reaction | 29 |
one year | 29 |
rgn replicon | 29 |
zikv infected | 29 |
herpes simplex | 28 |
case report | 28 |
acid signaling | 28 |
tissue culture | 28 |
cell types | 28 |
total number | 28 |
packaging cells | 28 |
immune cells | 28 |
systematic review | 28 |
yap island | 28 |
graphpad prism | 28 |
cells infected | 28 |
blood management | 27 |
emerging infectious | 27 |
case series | 27 |
plasma exchange | 27 |
transfusion services | 27 |
two different | 27 |
infectious clone | 27 |
rna replication | 27 |
ediii protein | 27 |
one patient | 27 |
well plate | 27 |
ns protein | 27 |
hemolytic transfusion | 27 |
east respiratory | 27 |
sequence repeats | 27 |
case presentation | 27 |
breast milk | 27 |
middle east | 27 |
rare consensus | 27 |
viral entry | 27 |
immune system | 27 |
significantly lower | 27 |
rhesus macaques | 27 |
serum samples | 26 |
igg antibodies | 26 |
patient safety | 26 |
aurintricarboxylic acid | 26 |
time rt | 26 |
pcr assay | 26 |
blood banks | 26 |
blood component | 26 |
acute respiratory | 26 |
bovine serum | 26 |
virus titers | 26 |
consensus sequence | 26 |
fetal interface | 26 |
health care | 26 |
birth defects | 26 |
envelope protein | 26 |
antiviral agents | 26 |
least one | 25 |
zikv mr | 25 |
differential diagnosis | 25 |
american red | 25 |
high titer | 25 |
month period | 25 |
significantly increased | 25 |
authors declare | 25 |
virus particles | 25 |
antibody identification | 25 |
simplex virus | 25 |
zikv inoculation | 25 |
cell disease | 25 |
study period | 25 |
virus type | 25 |
patient samples | 24 |
clinical trial | 24 |
false positive | 24 |
rgn strain | 24 |
flow cytometric | 24 |
lethal mutagenesis | 24 |
positive results | 24 |
measured using | 24 |
years old | 24 |
severe acute | 24 |
serial dilutions | 24 |
first trimester | 24 |
human cytomegalovirus | 24 |
two groups | 24 |
real time | 24 |
barre syndrome | 24 |
resonance imaging | 24 |
arboviral diseases | 24 |
virus transmission | 24 |
motor neurons | 24 |
zikv activity | 24 |
bact alert | 24 |
progenitor cells | 24 |
inhibitory activity | 24 |
emergency department | 24 |
monoclonal antibody | 24 |
gene expression | 23 |
zika viruses | 23 |
three days | 23 |
fetal mri | 23 |
soft tissue | 23 |
neutralizing activities | 23 |
class i | 23 |
adverse effects | 23 |
clinical practice | 23 |
previous studies | 23 |
electronic medical | 23 |
new york | 23 |
significant reduction | 23 |
enveloped viruses | 23 |
immunodeficiency virus | 23 |
aedes mosquitoes | 23 |
inhibit zikv | 23 |
platelet counts | 23 |
time point | 23 |
mouse models | 23 |
rescued virus | 23 |
creative commons | 23 |
rna virus | 23 |
urine samples | 23 |
platelet concentrates | 23 |
brazil zika | 23 |
neural tube | 22 |
serially diluted | 22 |
virus zika | 22 |
culture supernatants | 22 |
high levels | 22 |
transfusion practice | 22 |
head trauma | 22 |
dna vaccine | 22 |
fruit bats | 22 |
determine whether | 22 |
dependent manner | 22 |
human immunodeficiency | 22 |
neural progenitors | 22 |
molecular testing | 22 |
increased risk | 22 |
neutralizing activity | 22 |
total rna | 22 |
placental barrier | 22 |
virus infects | 22 |
male mice | 22 |
cells using | 22 |
time period | 22 |
units transfused | 22 |
neural progenitor | 22 |
antiviral activities | 22 |
stress granules | 22 |
zikv genome | 22 |
determined using | 22 |
virus rna | 21 |
host factors | 21 |
infected patients | 21 |
virus production | 21 |
cord blood | 21 |
standard deviation | 21 |
university hospital | 21 |
donor center | 21 |
blood safety | 21 |
important role | 21 |
predictive value | 21 |
intensive care | 21 |
two independent | 21 |
human placental | 21 |
disease control | 21 |
rna polymerase | 21 |
evaluated using | 21 |
virus pathogenesis | 21 |
regional blood | 21 |
mayo clinic | 21 |
frozen plasma | 21 |
test results | 21 |
mice infected | 21 |
zikv diagnostics | 21 |
iu ml | 20 |
per year | 20 |
commercially available | 20 |
inhibits zika | 20 |
year period | 20 |
federated states | 20 |
kindly provided | 20 |
neurological disorders | 20 |
reference laboratory | 20 |
transfusion protocol | 20 |
salivary gland | 20 |
forming units | 20 |
parental virus | 20 |
congenital infection | 20 |
washed three | 20 |
old female | 20 |
information system | 20 |
hemolytic anemia | 20 |
adc values | 20 |
zika fever | 20 |
protein synthesis | 20 |
significantly decreased | 20 |
per month | 20 |
ionizing radiation | 20 |
mice treated | 20 |
bacterial contamination | 20 |
platelet products | 20 |
virus ns | 20 |
inventory management | 20 |
prospective study | 20 |
data showed | 20 |
different time | 20 |
present study | 20 |
plasma samples | 20 |
amniotic fluid | 20 |
scd patients | 20 |
post mortem | 20 |
flaviviridae family | 19 |
therapeutic plasma | 19 |
lumbosacral spinal | 19 |
body fluids | 19 |
zikv outbreak | 19 |
hematopoietic stem | 19 |
apheresis platelet | 19 |
cerebrospinal fluid | 19 |
health emergency | 19 |
recent studies | 19 |
retrospective analysis | 19 |
cd deficiency | 19 |
canadian blood | 19 |
control group | 19 |
structural proteins | 19 |
average number | 19 |
blood collection | 19 |
linear regression | 19 |
cell cycle | 19 |
restriction sites | 19 |
vaccine candidates | 19 |
also tested | 19 |
plasma units | 19 |
dengue viruses | 19 |
zikv transmission | 19 |
rhd gene | 19 |
intrinsic disorder | 19 |
neural stem | 19 |
samples tested | 19 |
asian lineage | 19 |
inhibited zikv | 19 |
supplementary document | 19 |
cell cultures | 19 |
reading frame | 19 |
infectious clones | 19 |
ct scan | 19 |
log copies | 19 |
ediii alone | 19 |
zikv vaccine | 19 |
congenital anomalies | 19 |
trauma patients | 19 |
physical examination | 19 |
type ii | 19 |
buffered saline | 19 |
supplementary table | 19 |
platelet inventory | 19 |
animal model | 19 |
deferral rates | 19 |
rare donor | 18 |
calculated using | 18 |
aedes albopictus | 18 |
endemic areas | 18 |
severe disease | 18 |
specific antibody | 18 |
positive control | 18 |
hong kong | 18 |
crystal violet | 18 |
four patients | 18 |
national blood | 18 |
logistic regression | 18 |
infectious particles | 18 |
pediatric population | 18 |
lamp assay | 18 |
zika vaccine | 18 |
lymph nodes | 18 |
first time | 18 |
graphpad software | 18 |
patients received | 18 |
diagnostic tests | 18 |
usutu virus | 18 |
platelet units | 18 |
volume reduction | 18 |
iron deficiency | 18 |
may provide | 18 |
hospital transfusion | 18 |
brain barrier | 18 |
final concentration | 18 |
signal intensity | 18 |
african genotype | 18 |
protein ns | 18 |
rbc transfusions | 18 |
cell membranes | 18 |
retrospective review | 18 |
also observed | 18 |
interferon signaling | 18 |
cells transfected | 18 |
sertoli cells | 18 |
symptom onset | 18 |
antigen expression | 18 |
shell disorder | 18 |
fetal bovine | 18 |
infects human | 17 |
strain prvabc | 17 |
age group | 17 |
dtt treatment | 17 |
risk factor | 17 |
eu eea | 17 |
medium containing | 17 |
pediatric radiologists | 17 |
vitro quality | 17 |
hcmv infection | 17 |
brain organoids | 17 |
subunit vaccine | 17 |
hospital background | 17 |
imaging techniques | 17 |
blood ordering | 17 |
membrane fusion | 17 |
fetal demise | 17 |
widely used | 17 |
different cell | 17 |
genome sequence | 17 |
gold standard | 17 |
last years | 17 |
previous study | 17 |
rejuvenation solution | 17 |
zikv isolates | 17 |
ifitm proteins | 17 |
congenital zikv | 17 |
shelf life | 17 |
amino acids | 17 |
neurological complications | 17 |
stranded rna | 17 |
abdominal pain | 17 |
rhd beadchip | 17 |
life technologies | 17 |
median age | 17 |
monoclonal anti | 17 |
egfp reporter | 17 |
chest ct | 17 |
goat anti | 17 |
human brain | 17 |
donor screening | 17 |
treated rbcs | 17 |
genome replication | 17 |
regression analysis | 17 |
coding regions | 17 |
zikv particles | 17 |
different concentrations | 17 |
per well | 17 |
days later | 17 |
cellular stress | 17 |
female donors | 17 |
epithelial cells | 17 |
polymerase chain | 17 |
see table | 17 |
western hemisphere | 17 |
pathogen inactivation | 17 |
cell monolayers | 17 |
low levels | 17 |
platelet transfusion | 17 |
dsdna viruses | 17 |
seven days | 16 |
per patient | 16 |
fresh frozen | 16 |
emerging viral | 16 |
hours post | 16 |
transfected cells | 16 |
blood system | 16 |
brain endothelial | 16 |
zika igg | 16 |
chain reaction | 16 |
washed twice | 16 |
nk cell | 16 |
clinical outcomes | 16 |
cohort study | 16 |
donor samples | 16 |
nucleotide sequences | 16 |
white blood | 16 |
virus genome | 16 |
growth medium | 16 |
future studies | 16 |
another study | 16 |
patients undergoing | 16 |
case reports | 16 |
growth factor | 16 |
even though | 16 |
virus strains | 16 |
jamaican fruit | 16 |
antiviral effect | 16 |
serologic testing | 16 |
repeat testing | 16 |
clinical symptoms | 16 |
infectious cdna | 16 |
significantly reduced | 16 |
replication cycle | 16 |
abusive head | 16 |
ml kg | 16 |
isothermal amplification | 16 |
new automated | 16 |
unfolded protein | 16 |
leucocyte depleted | 16 |
high resolution | 16 |
coding region | 16 |
laboratory testing | 16 |
influenza vaccine | 16 |
genomic dna | 16 |
scale bar | 16 |
patients receiving | 16 |
blood service | 16 |
cells per | 16 |
culture media | 16 |
whole body | 16 |
tertiary care | 16 |
fetal morbidity | 16 |
contrast enhanced | 16 |
data suggest | 16 |
serological specificity | 16 |
endemic regions | 16 |
plaque reduction | 16 |
electron microscopy | 16 |
standard curve | 16 |
manual tube | 16 |
ns proteins | 16 |
similar results | 16 |
pcr products | 16 |
vero cell | 16 |
tube testing | 16 |
secondary antibody | 16 |
nonstructural protein | 16 |
antibody screening | 16 |
congenital cytomegalovirus | 16 |
tcid ml | 16 |
weighted imaging | 15 |
fluorescence intensity | 15 |
voluntary blood | 15 |
study demonstrated | 15 |
trophoblast cells | 15 |
high prevalence | 15 |
patients showed | 15 |
cd cd | 15 |
brain tissues | 15 |
virus stocks | 15 |
nonstructural proteins | 15 |
inhibitory effects | 15 |
reverse genetic | 15 |
infection zika | 15 |
congenital brain | 15 |
negative blood | 15 |
inhibits zikv | 15 |
western pacific | 15 |
diagnostic tool | 15 |
reagent red | 15 |
solid phase | 15 |
false negative | 15 |
cell transplantation | 15 |
results show | 15 |
recently developed | 15 |
serum albumin | 15 |
whether zikv | 15 |
severe neurological | 15 |
disease virus | 15 |
additive solution | 15 |
ferritin levels | 15 |
acute phase | 15 |
care unit | 15 |
terumo bct | 15 |
adverse reactions | 15 |
gestational age | 15 |
rbc unit | 15 |
one hour | 15 |
krrk basic | 15 |
western blot | 15 |
significant increase | 15 |
fda approved | 15 |
mosquito bites | 15 |
antiviral drug | 15 |
human serum | 15 |
cellular immune | 15 |
rhd diiia | 15 |
cell lysates | 15 |
molecular detection | 15 |
antiglobulin test | 15 |
uninfected cells | 15 |
high risk | 15 |
immunosuppressed mice | 15 |
image quality | 15 |
amotosalen uva | 15 |
asian genotype | 15 |
stored rbcs | 15 |
rbcs stored | 15 |
olfactory ensheathing | 15 |
described previously | 15 |
using anti | 15 |
among different | 15 |
basic residues | 15 |
zikv may | 15 |
long term | 15 |
supernumerary centrin | 15 |
fold increase | 15 |
weighted images | 15 |
viral envelope | 15 |
imaging modality | 15 |
quality improvement | 15 |
centrin foci | 15 |
detect zikv | 15 |
commonly used | 15 |
time course | 14 |
emergency release | 14 |
ct examinations | 14 |
human skin | 14 |
hcv rna | 14 |
corpus callosum | 14 |
neg rbc | 14 |
er membrane | 14 |
mediated endocytosis | 14 |
cells well | 14 |
radiation exposure | 14 |
human neural | 14 |
protein response | 14 |
mediated isothermal | 14 |
patient population | 14 |
side effects | 14 |
comparator assay | 14 |
protective efficacy | 14 |
zikv envelope | 14 |
chloroquine treatment | 14 |
brain tissue | 14 |
pandemic influenza | 14 |
virus detection | 14 |
recent study | 14 |
infected individuals | 14 |
blood screening | 14 |
ct scans | 14 |
error bars | 14 |
copyright holder | 14 |
old male | 14 |
direct antiglobulin | 14 |
viral pathogens | 14 |
flow cytometer | 14 |
detection limit | 14 |
zika forest | 14 |
hemolytic disease | 14 |
live attenuated | 14 |
plaque forming | 14 |
trauma center | 14 |
blood systems | 14 |
fresh medium | 14 |
pathogen reduced | 14 |
healthy volunteers | 14 |
human pregnancy | 14 |
tested using | 14 |
zikv neonates | 14 |
human infection | 14 |
old girl | 14 |
turnaround time | 14 |
multiple comparison | 14 |
spinal motor | 14 |
renal function | 14 |
pluripotent stem | 14 |
likely due | 14 |
clinical signs | 14 |
febrile illness | 14 |
developing fetus | 14 |
zikv infectious | 14 |
expression levels | 14 |
treated zikv | 14 |
rbc products | 14 |
results indicate | 14 |
three independent | 14 |
dexamethasone immunosuppression | 14 |
vector control | 14 |
tissue tropism | 14 |
antibody screens | 14 |
tube method | 14 |
cytomegalovirus infection | 14 |
significant antibodies | 14 |
donor population | 14 |
small number | 14 |
positive cells | 14 |
sciatic nerve | 14 |
urinary tract | 14 |
cells may | 14 |
human plasma | 14 |
blood transfusions | 14 |
pilot study | 14 |
ms ms | 14 |
antibody responses | 14 |
two patients | 14 |
virus particle | 14 |
using two | 14 |
hemoglobin levels | 14 |
male donors | 14 |
zikv ir | 14 |
zika vrna | 14 |
confocal microscopy | 14 |
rhesus macaque | 14 |
protein kinase | 14 |
reduced viral | 14 |
rare sequence | 14 |
mice immunized | 14 |
sexual contact | 14 |
negative rbcs | 14 |
iron metabolism | 14 |
high frequency | 14 |
risk assessment | 14 |
transfusion testing | 13 |
control study | 13 |
borne transmission | 13 |
storage lesion | 13 |
mass spectrometry | 13 |
genotyping results | 13 |
alexa fluor | 13 |
generation sequencing | 13 |
aegypti mosquitoes | 13 |
obtained using | 13 |
plasma membranes | 13 |
sperm count | 13 |
single unit | 13 |
antiviral efficacy | 13 |
yap state | 13 |
performed within | 13 |
perinatal transmission | 13 |
single adjuvant | 13 |
transfused patients | 13 |
like activity | 13 |
emergency blood | 13 |
clinical presentation | 13 |
early stage | 13 |
slightly lower | 13 |
mr zikv | 13 |
take home | 13 |
commons license | 13 |
informed consent | 13 |
one unit | 13 |
rhd genotyping | 13 |
human strains | 13 |
virus strain | 13 |
transfusion transmitted | 13 |
hla antibodies | 13 |
clinical manifestations | 13 |
mg cells | 13 |
recent outbreak | 13 |
congenital heart | 13 |
donated blood | 13 |
assessed using | 13 |
irradiated blood | 13 |
motor cortex | 13 |
one month | 13 |
human igg | 13 |
zikv prm | 13 |
several studies | 13 |
health concern | 13 |
dengue vaccine | 13 |
three patients | 13 |
culture supernatant | 13 |
antiviral drugs | 13 |
low ferritin | 13 |
thermofisher scientific | 13 |
ex vivo | 13 |
diagnostic accuracy | 13 |
mouse sera | 13 |
san diego | 13 |
also found | 13 |
vaccine design | 13 |
primary human | 13 |
renal failure | 13 |
confirmed positive | 13 |
antibody titer | 13 |
home points | 13 |
statistical analyses | 13 |
early diagnosis | 13 |
denv serotypes | 13 |
viral genomes | 13 |
huh cells | 13 |
new world | 13 |
immune evasion | 13 |
centrosome organization | 13 |
genital tract | 13 |
transplant recipients | 13 |
standard tube | 13 |
brain development | 13 |
investigate whether | 13 |
transmembrane protein | 13 |
case study | 13 |
one hundred | 13 |
buffy coat | 13 |
may lead | 13 |
antiviral effects | 13 |
escherichia coli | 13 |
within days | 13 |
results demonstrate | 13 |
university school | 13 |
inhibitory effect | 13 |
mononuclear cells | 13 |
international license | 13 |
strains tested | 13 |
literature review | 13 |
antiviral agent | 13 |
blood count | 13 |
primary antibodies | 13 |
rapid spread | 12 |
sanger sequencing | 12 |
innate immunity | 12 |
developing fetuses | 12 |
molecular diagnostic | 12 |
indirect immunofluorescence | 12 |
blocking solution | 12 |
replacement fluid | 12 |
sequence analysis | 12 |
igg antibody | 12 |
codon usage | 12 |
contrast media | 12 |
subunit vaccines | 12 |
diagnostic test | 12 |
imaging procedures | 12 |
also reported | 12 |
examination revealed | 12 |
specific primers | 12 |
mutation frequencies | 12 |
rgn infectious | 12 |
molecular weight | 12 |
mpl adjuvants | 12 |
congenital malformations | 12 |
persistent infection | 12 |
congenital disease | 12 |
associated protein | 12 |
third trimester | 12 |
see supplementary | 12 |
predicted phenotype | 12 |
allowed us | 12 |
suspected cases | 12 |
thawed plasma | 12 |
secondary antibodies | 12 |
academic medical | 12 |
small bowel | 12 |
mammalian cells | 12 |
first isolated | 12 |
oxidative stress | 12 |
primary antibody | 12 |
made available | 12 |
alloimmunized patients | 12 |
family members | 12 |
group system | 12 |
infection induces | 12 |
nat yield | 12 |
age groups | 12 |
treatment group | 12 |
rhd weak | 12 |
immature platelet | 12 |
viral pandemics | 12 |
high throughput | 12 |
molecular mechanisms | 12 |
relatively low | 12 |
possible association | 12 |
risks associated | 12 |
specific mabs | 12 |
accession number | 12 |
two cases | 12 |
growth kinetics | 12 |
intracellular trafficking | 12 |
cells treated | 12 |
control mice | 12 |
vps score | 12 |
mpl adjuvant | 12 |
rhd negative | 12 |
lipase activity | 12 |
infected mothers | 12 |
ns gene | 12 |
significant impact | 12 |
mosquito species | 12 |
hcmv infected | 12 |
large number | 12 |
rabies virus | 12 |
reactive samples | 12 |
cost savings | 12 |
first case | 12 |
days following | 12 |
cytopathic effect | 12 |
brain defects | 12 |
cmv promoter | 12 |
nucleoside analogues | 12 |
much lower | 12 |
donate blood | 12 |
antigen negative | 12 |
cells ml | 12 |
hospital blood | 12 |
based transfusion | 12 |
higher levels | 12 |
pregnancy outcomes | 12 |
color doppler | 12 |
old boy | 12 |
per group | 12 |
management system | 12 |
blood supplier | 12 |
clinical use | 12 |
vast majority | 12 |
seminiferous tubules | 12 |
virus life | 12 |
results indicated | 12 |
signaling pathway | 12 |
two years | 12 |
global health | 12 |
kir ds | 12 |
one day | 12 |
vaccine clinical | 12 |
will also | 12 |
approved drugs | 12 |
zika infection | 12 |
mini kit | 12 |
pleural effusion | 12 |
log ec | 12 |
antibody levels | 12 |
buffy coats | 12 |
marrow edema | 12 |
transfusion recipients | 12 |
stress granule | 12 |
reduced zikv | 12 |
te cells | 12 |
dmem containing | 12 |
cell membrane | 12 |
stress response | 12 |
dengue fever | 12 |
based blood | 12 |
per unit | 12 |
iron overload | 12 |
study aimed | 12 |
recipient cells | 12 |
vascular malformations | 12 |
associated microcephaly | 11 |
abo typing | 11 |
recombinant zikv | 11 |
transfusion safety | 11 |
central venous | 11 |
semen samples | 11 |
cell processor | 11 |
nip rhd | 11 |
parental mr | 11 |
human cortical | 11 |
iron depletion | 11 |
ns protease | 11 |
hbv dna | 11 |
results demonstrated | 11 |
blood pressure | 11 |
reference standard | 11 |
cause fetal | 11 |
purified zikv | 11 |
reduction neutralization | 11 |
clinical data | 11 |
calculated based | 11 |
mice zika | 11 |
clinical diagnosis | 11 |
strain pan | 11 |
cd cell | 11 |
data show | 11 |
automated bp | 11 |
significantly associated | 11 |
patient received | 11 |
best practice | 11 |
donor plasma | 11 |
author funder | 11 |
protective immunity | 11 |
hod otii | 11 |
single ventricle | 11 |
hemorrhagic fever | 11 |
plt count | 11 |
neutralize zikv | 11 |
post thaw | 11 |
reverse genetics | 11 |
brain abnormalities | 11 |
regional office | 11 |
may play | 11 |
cell cycles | 11 |
based approach | 11 |
cell migration | 11 |
inflammatory response | 11 |
forward primer | 11 |
screening test | 11 |
cell units | 11 |
split rate | 11 |
immunocompetent mice | 11 |
zikv compound | 11 |
observed using | 11 |
neuroglial cells | 11 |
skull base | 11 |
female mice | 11 |
randomization models | 11 |
blood specimens | 11 |
phone calls | 11 |
treated group | 11 |
compatible blood | 11 |
two days | 11 |
ab plasma | 11 |
critically ill | 11 |
mg ml | 11 |
chronic hepatitis | 11 |
new england | 11 |
randomized controlled | 11 |
mean fluorescence | 11 |
hela cells | 11 |
linked immunosorbent | 11 |
emerging viruses | 11 |
also performed | 11 |
fluorescent protein | 11 |
early stages | 11 |
protein folding | 11 |
denv infection | 11 |
study zika | 11 |
plasma replacement | 11 |
studies showed | 11 |
cep gt | 11 |
adverse pregnancy | 11 |
fetal transmission | 11 |
binding protein | 11 |
samples collected | 11 |
bars represent | 11 |
genbank accession | 11 |
dengue infection | 11 |
surface antigen | 11 |
health system | 11 |
pcr system | 11 |
hematology analyzer | 11 |
mouse anti | 11 |
cell interactions | 11 |
host interactions | 11 |
host ap | 11 |
cd tregs | 11 |
analysis revealed | 11 |
umbilical cord | 11 |
csp bj | 11 |
may contribute | 11 |
considered significant | 11 |
exact test | 11 |
cell lysate | 11 |
rna levels | 11 |
tested positive | 11 |
negative results | 11 |
past years | 11 |
large volume | 11 |
clinical outcome | 11 |
early detection | 11 |
hb deferral | 11 |
study shows | 11 |
borne encephalitis | 11 |
also inhibits | 11 |
medical records | 11 |
patient outcomes | 11 |
apheresis donors | 11 |
granted medrxiv | 11 |
serologic properties | 11 |
human zikv | 11 |
ensheathing cells | 11 |
multiple myeloma | 11 |
cxcr pd | 11 |
peer review | 11 |
human monoclonal | 11 |
response rate | 11 |
assay using | 11 |
adverse outcomes | 11 |
lysis buffer | 11 |
patient harm | 11 |
micronesia zika | 11 |
three cases | 11 |
data set | 11 |
normal limits | 11 |
five days | 11 |
syndrome outbreak | 11 |
also evaluated | 11 |
randomly selected | 11 |
rh typing | 11 |
signaling dysregulation | 11 |
tranexamic acid | 11 |
second dose | 11 |
wide range | 11 |
random variants | 11 |
within normal | 11 |
different zikv | 11 |
titer anti | 11 |
technician related | 11 |
phase clinical | 11 |
global public | 11 |
pet ct | 11 |
human primates | 11 |
laboratory data | 11 |
analysis showed | 11 |
platelet transfusions | 11 |
juvenile idiopathic | 11 |
rabbit anti | 11 |
positive predictive | 11 |
african americans | 11 |
slightly higher | 11 |
antigen typing | 11 |
reproductive organs | 11 |
may help | 11 |
reverse primer | 11 |
significantly improved | 11 |
fold serial | 11 |
flavivirus infection | 11 |
automated alinity | 11 |
intracellular viral | 11 |
course study | 11 |
dpg levels | 11 |
brain malformations | 11 |
may cause | 11 |
gastrocnemius muscle | 11 |
healthy children | 10 |
borne viruses | 10 |
also determined | 10 |
ethics committee | 10 |
borne virus | 10 |
prism software | 10 |
first line | 10 |
cold pbs | 10 |
virus targets | 10 |
plaque size | 10 |
forming assay | 10 |
rna extraction | 10 |
brazil zikv | 10 |
brazilian zika | 10 |
human antibody | 10 |
interferon treatment | 10 |
mr virus | 10 |
immunofluorescence staining | 10 |
false positives | 10 |
hindlimb motor | 10 |
weeks old | 10 |
rbc storage | 10 |
outbreak associated | 10 |
donor program | 10 |
id rhd | 10 |
ill patients | 10 |
deep learning | 10 |
final diagnosis | 10 |
study demonstrates | 10 |
pondr vlxt | 10 |
hla class | 10 |
nucleotide sequence | 10 |
axial disease | 10 |
unfolded proteins | 10 |
purified inactivated | 10 |
rhesus monkeys | 10 |
per animal | 10 |
pathogenic mutations | 10 |
microcephaly cases | 10 |
green monkey | 10 |
chart review | 10 |
cell entry | 10 |
posted march | 10 |
donor unit | 10 |
spectra optia | 10 |
disease pathogenesis | 10 |
acute infection | 10 |
fold dilutions | 10 |
human mabs | 10 |
rhd xt | 10 |
diagnostic imaging | 10 |
cohort studies | 10 |
duke university | 10 |
positive antibody | 10 |
cell proliferation | 10 |
drug administration | 10 |
monitored daily | 10 |
two distinct | 10 |
left ventricle | 10 |
cortical neural | 10 |
polyethylene glycol | 10 |
cell surface | 10 |
inclusion criteria | 10 |
result verification | 10 |
specificity zika | 10 |
plasmid containing | 10 |
product wastage | 10 |
three zikv | 10 |
platelet additive | 10 |
serologic weak | 10 |
liver transplantation | 10 |
modification systems | 10 |
infected vero | 10 |
tissue factor | 10 |
zais qds | 10 |
virus vaccine | 10 |
packed red | 10 |
compared using | 10 |
limited data | 10 |
data points | 10 |
transmitted zika | 10 |
following zikv | 10 |
chronically transfused | 10 |
version posted | 10 |
days prior | 10 |
total volume | 10 |
apheresis procedures | 10 |
ttp patients | 10 |
viral titer | 10 |
pcr detection | 10 |
fresenius kabi | 10 |
based zikv | 10 |
previously healthy | 10 |
cause severe | 10 |
day post | 10 |
virucidal activity | 10 |
er lumen | 10 |
natural infection | 10 |
analysed using | 10 |
ap donors | 10 |
infectious titer | 10 |
studies will | 10 |
copies per | 10 |
influenza viruses | 10 |
post collection | 10 |
vascular anomalies | 10 |
experimental models | 10 |
away time | 10 |
us blood | 10 |
htlv i | 10 |
blood banking | 10 |
patient identification | 10 |
clinical diagnostics | 10 |
using graphpad | 10 |
among blood | 10 |
lower levels | 10 |
idiopathic arthritis | 10 |
rbc alloimmunization | 10 |
histological analysis | 10 |
samples obtained | 10 |
blood groups | 10 |
attenuated zikv | 10 |
previously published | 10 |
platelet recovery | 10 |
immunohematology reference | 10 |
many viruses | 10 |
phylogenetic analysis | 10 |
new process | 10 |
ct angiography | 10 |
age range | 10 |
following day | 10 |
genus flavivirus | 10 |
single donor | 10 |
mps iva | 10 |
infectious agents | 10 |
way valve | 10 |
heart disease | 10 |
patients requiring | 10 |
testing using | 10 |
therapeutic potential | 10 |
medical students | 10 |
respiratory tract | 10 |
healthy donors | 10 |
least two | 10 |
sf cells | 10 |
pfu cell | 10 |
cd expression | 10 |
bowel wall | 10 |
reference laboratories | 10 |
avian influenza | 10 |
wbc count | 10 |
contrast enhancement | 10 |
acid sequence | 10 |
titer results | 10 |
five patients | 10 |
vena cava | 10 |
using flow | 10 |
also showed | 10 |
detected using | 10 |
bac cdna | 10 |
doppler us | 10 |
african green | 10 |
reading frames | 10 |
mhc class | 10 |
stored rbc | 10 |
factors associated | 10 |
zikv epidemic | 10 |
abo bw | 10 |
sample collection | 10 |
peg iat | 10 |
research institute | 10 |
childbearing age | 10 |
reported cases | 10 |
cross blood | 10 |
zkv testing | 10 |
baby units | 10 |
digital radiography | 10 |
rna level | 10 |
data management | 10 |
gene sequencing | 10 |
crossing vessels | 10 |
using standard | 10 |
dendritic cells | 10 |
clinically relevant | 10 |
human diseases | 10 |
key role | 10 |
tissue sections | 10 |
rbc alloantibodies | 10 |
specific antibodies | 10 |
i interferons | 10 |
master mix | 10 |
standard deviations | 10 |
molecular evolution | 10 |
sybr green | 10 |
investigated whether | 10 |
medicine background | 10 |
sciatic notch | 10 |
translation initiation | 10 |
african lineage | 10 |
storage period | 10 |
reverse transcriptase | 10 |
london uk | 10 |
early pregnancy | 10 |
neutralization assay | 10 |
cell tropism | 10 |
dependent rna | 10 |
commons attribution | 10 |
complete protection | 10 |
underrepresented sequences | 10 |
zikv pathogenesis | 10 |
crossmatch compatible | 10 |
lipid metabolism | 10 |
task force | 10 |
positive er | 10 |
rpe cells | 10 |
com scientificreports | 10 |
pacific region | 10 |
nonhuman primate | 10 |
delayed hemolytic | 9 |
human antibodies | 9 |
attachment activity | 9 |
body mri | 9 |
laboratories indicated | 9 |
pediatric patient | 9 |
clinical course | 9 |
willebrand factor | 9 |
pg ml | 9 |
york blood | 9 |
cause congenital | 9 |
scoring system | 9 |
systematic reviews | 9 |
malignant lesions | 9 |
chemical proteomics | 9 |
us examination | 9 |
animal care | 9 |
viral persistence | 9 |
mouse igg | 9 |
zikv cdna | 9 |
four days | 9 |
plasma wastage | 9 |
thrombocytopenic purpura | 9 |
cerus corporation | 9 |
retrospectively reviewed | 9 |
infectious dose | 9 |
three groups | 9 |
dose zikv | 9 |
first report | 9 |
wall thickening | 9 |
ct findings | 9 |
immucor neo | 9 |
trima accel | 9 |
much higher | 9 |
horseradish peroxidase | 9 |
diffusion restriction | 9 |
zikv isolate | 9 |
viral particle | 9 |
congenital pulmonary | 9 |
autoimmune hemolytic | 9 |
transfusion practices | 9 |
developing brain | 9 |
os cells | 9 |
patients treated | 9 |
additional information | 9 |
page followed | 9 |
clone anti | 9 |
international concern | 9 |
based assay | 9 |
rhd variant | 9 |
also demonstrated | 9 |
different types | 9 |
global threat | 9 |
rhesus monkey | 9 |
closed system | 9 |
latin america | 9 |
cells derived | 9 |
rbc antigens | 9 |
among men | 9 |
ge healthcare | 9 |
platelet adhesion | 9 |
suckling mice | 9 |
brazilian zikv | 9 |
several viruses | 9 |
protein mab | 9 |
upper gi | 9 |
generated using | 9 |
will provide | 9 |
safe blood | 9 |
nat screening | 9 |
routine quality | 9 |
positive donations | 9 |
lethal challenge | 9 |
week period | 9 |
rbc exchange | 9 |
allogeneic blood | 9 |
hla antibody | 9 |
tested negative | 9 |
copy number | 9 |
spondweni virus | 9 |
wide spectrum | 9 |
volume processed | 9 |
cells kg | 9 |
human blood | 9 |
post transfusion | 9 |
genomic rna | 9 |
reporter gene | 9 |
bacterial culture | 9 |
zikv asian | 9 |
clinical syndromes | 9 |
cell fate | 9 |
better understanding | 9 |
zikv full | 9 |
effective treatment | 9 |
forming unit | 9 |
high titers | 9 |
reproductive tract | 9 |
sexually transmitted | 9 |
virus isolation | 9 |
abdominal trauma | 9 |
ediii proteins | 9 |
hla typing | 9 |
pizv dose | 9 |
sample size | 9 |
growth curve | 9 |
platelet components | 9 |
virus vaccines | 9 |
tubular matrix | 9 |
number ku | 9 |
rhce cehar | 9 |
second sample | 9 |
cmap amplitudes | 9 |
positive dat | 9 |
septic transfusion | 9 |
african american | 9 |
domain iii | 9 |
von willebrand | 9 |
crosslinked proteins | 9 |
nuclear import | 9 |
human coronavirus | 9 |
closely related | 9 |
zikv molecular | 9 |
current status | 9 |
comparison tests | 9 |
interacting proteins | 9 |
open access | 9 |
inventory levels | 9 |
viral dna | 9 |
cell histiocytosis | 9 |
compound control | 9 |
radiation dose | 9 |
ortho clinical | 9 |
liquid plasma | 9 |
different stages | 9 |
study days | 9 |
neutralizing monoclonal | 9 |
literature search | 9 |
broadly neutralizing | 9 |
natural killer | 9 |
previous reports | 9 |
competing interests | 9 |
microcephaly associated | 9 |
units per | 9 |
strong correlation | 9 |
cell response | 9 |
better understand | 9 |
human neutralizing | 9 |
flavivirus genus | 9 |
per milliliter | 9 |
induced pluripotent | 9 |
institutional review | 9 |
improve patient | 9 |
motor neuron | 9 |
mesenchymal stem | 9 |
immunized mice | 9 |
humoral response | 9 |
neutralizing human | 9 |
zikv sequences | 9 |
plasma volume | 9 |
human fetal | 9 |
progeny yield | 9 |
also identified | 9 |
gt gt | 9 |
brain structures | 9 |
control measures | 9 |
reticulum stress | 9 |
serological tests | 9 |
acute pancreatitis | 9 |
kidney transplant | 9 |
indirect antiglobulin | 9 |
also used | 9 |
within weeks | 9 |
one week | 9 |
wild type | 9 |
vaccine platforms | 9 |
advisory committee | 9 |
cell collection | 9 |
laboratory information | 9 |
adult patients | 9 |
i ii | 9 |
optic nerve | 9 |
mr plasmid | 9 |
high sensitivity | 9 |
per ml | 9 |
inferior vena | 9 |
three different | 9 |
untreated control | 9 |
evidence based | 9 |
placental tissues | 9 |
teg results | 9 |
glial cells | 9 |
coding sequences | 9 |
total blood | 9 |
infected animals | 9 |
patients underwent | 9 |
platelet collections | 9 |
among patients | 9 |
patients without | 9 |
surgical treatment | 9 |
tumor volume | 9 |
high specificity | 9 |
gene sequences | 9 |
induce cellular | 9 |
may affect | 9 |
pe patients | 9 |
virus growth | 9 |
antibodies prevent | 9 |
paediatric patients | 9 |
dna fragments | 9 |
binding site | 9 |
multiple comparisons | 9 |
phase red | 9 |
diffusion weighted | 9 |
zikv entry | 9 |
surgical blood | 9 |
next generation | 9 |
er density | 9 |
restriction enzyme | 9 |
mdck cells | 9 |
skin cells | 9 |
broad range | 9 |
emerging arbovirus | 9 |
blood derived | 9 |
factor viii | 9 |
study also | 9 |
failed runs | 9 |
south pacific | 9 |
blood order | 9 |
clinic background | 9 |
blood sample | 9 |
vertebrate hosts | 9 |
inhibit viral | 9 |
viral membrane | 9 |
examined whether | 9 |
dna replication | 9 |
highly conserved | 9 |
paediatric radiology | 9 |
limited number | 9 |
observer agreement | 9 |
quantitative pcr | 9 |
healthy adults | 9 |
ediii subunit | 9 |
mean number | 9 |
thrombin generation | 8 |
normal saline | 8 |
per week | 8 |
respiratory symptoms | 8 |
hla matched | 8 |
viral disease | 8 |
broad spectrum | 8 |
hgb hct | 8 |
university medical | 8 |
emergency units | 8 |
aedes spp | 8 |
procedures performed | 8 |
national reference | 8 |
probably due | 8 |
human cd | 8 |
pak lx | 8 |
incubation period | 8 |
transforming growth | 8 |
structural basis | 8 |
emergency use | 8 |
rbc samples | 8 |
deficient mice | 8 |
disease activity | 8 |
iron supplementation | 8 |
mp content | 8 |
values obtained | 8 |
recombinant virus | 8 |
two zikv | 8 |
culture medium | 8 |
ns antigen | 8 |
cobe spectra | 8 |
monkey kidney | 8 |
american health | 8 |
computer program | 8 |
transfected packaging | 8 |
platelet yield | 8 |
antibodies isolated | 8 |
virus envelope | 8 |
rhd alleles | 8 |
decidual nk | 8 |
genetic analysis | 8 |
viruses zika | 8 |
conducted using | 8 |
may become | 8 |
using rt | 8 |
platelet usage | 8 |
also known | 8 |
observational study | 8 |
matched platelets | 8 |
quantified using | 8 |
using different | 8 |
seminiferous tubule | 8 |
peripheral neuropathy | 8 |
infected control | 8 |
vaccine efficacy | 8 |
prevent zikv | 8 |
serological testing | 8 |
neutralizing mabs | 8 |
clinical samples | 8 |
negative controls | 8 |
way analysis | 8 |
study performed | 8 |
immunohistochemical staining | 8 |
zikv group | 8 |
important implications | 8 |
molecular biology | 8 |
pan american | 8 |
specific hits | 8 |
chemical probe | 8 |
ag mouse | 8 |
laboratory operations | 8 |
oneg rbcs | 8 |
pediatric oncology | 8 |
north america | 8 |
dna viruses | 8 |
weakly positive | 8 |
biliary atresia | 8 |
pathogenic viruses | 8 |
markedly reduced | 8 |
virus stock | 8 |
homooligonucleotide repeats | 8 |
confer protection | 8 |
congenital duodenal | 8 |
data indicate | 8 |
may result | 8 |
three reading | 8 |
strain mr | 8 |
rare donors | 8 |
pacific islands | 8 |
epidemiological studies | 8 |
rare case | 8 |
rare cases | 8 |
irradiated rbcs | 8 |
wastage rates | 8 |
gel card | 8 |
plaque assays | 8 |
services background | 8 |
recent outbreaks | 8 |
correlation coefficient | 8 |
disordered regions | 8 |
zoster virus | 8 |
myc antibody | 8 |
interventional radiology | 8 |
primary infection | 8 |
immediate spin | 8 |
simulated transfusion | 8 |
cases reported | 8 |
bpn bottles | 8 |
first identified | 8 |
reduce zikv | 8 |
dtt treated | 8 |
fetal microcephaly | 8 |
vector competence | 8 |
viral life | 8 |
typing results | 8 |
different blood | 8 |
borne flavivirus | 8 |
also revealed | 8 |
patients may | 8 |
partial plasma | 8 |
spectrum anti | 8 |
clinical disease | 8 |
without affecting | 8 |
additional studies | 8 |
grade tumours | 8 |
represent mean | 8 |
zikv exposure | 8 |
dependent enhancement | 8 |
immunosorbent assay | 8 |
least three | 8 |
usage bias | 8 |
severe reaction | 8 |
cells expressing | 8 |
rheumatoid arthritis | 8 |
level i | 8 |
neutrophil infiltration | 8 |
tm cells | 8 |
complete blood | 8 |
cytometric method | 8 |
significant correlation | 8 |
matched units | 8 |
cmnc protocol | 8 |
culture infectious | 8 |
mab binding | 8 |
significant decrease | 8 |
cell antibodies | 8 |
inoculated onto | 8 |
laboratory results | 8 |
old woman | 8 |
affected areas | 8 |
igm positive | 8 |
infected male | 8 |
assay showed | 8 |
targeted mabs | 8 |
control samples | 8 |
dimethyl sulfoxide | 8 |
pcr test | 8 |
control groups | 8 |
calcusyn computer | 8 |
also associated | 8 |
storage duration | 8 |
triglyceride levels | 8 |
brain mri | 8 |
considered statistically | 8 |
plt units | 8 |
dna samples | 8 |
acute zika | 8 |
fever without | 8 |
initial presentation | 8 |
neutralization test | 8 |
vital organs | 8 |
activated protein | 8 |
final product | 8 |
brain edema | 8 |
primary hits | 8 |
different groups | 8 |
disease severity | 8 |
structural protein | 8 |
thrombotic thrombocytopenic | 8 |
dot represents | 8 |
waste management | 8 |
portal vein | 8 |
mm tris | 8 |
infectious viral | 8 |
time donors | 8 |
one study | 8 |
affected countries | 8 |
brazilian strain | 8 |
platelet clearance | 8 |
laboratory diagnosis | 8 |
human viruses | 8 |
virus causes | 8 |
controlled trials | 8 |
less likely | 8 |
oneg patients | 8 |
higher risk | 8 |
high incidence | 8 |
mr images | 8 |
infected cell | 8 |
automated solid | 8 |
rgn srip | 8 |
infected human | 8 |
third party | 8 |
critical role | 8 |
alloimmunization rates | 8 |
small numbers | 8 |
family flaviviridae | 8 |
pediatric radiologist | 8 |
technologist time | 8 |
group antigen | 8 |
brain microvascular | 8 |
analytical sensitivity | 8 |
ortho vision | 8 |
software version | 8 |
culture results | 8 |
automated gel | 8 |
male reproductive | 8 |
phase i | 8 |
also detected | 8 |
active inflammation | 8 |
spleen stiffness | 8 |
platelet refractoriness | 8 |
pe group | 8 |
transfusion related | 8 |
emergently issued | 8 |
different viruses | 8 |
low titer | 8 |
independent variables | 8 |
loading control | 8 |
scimitar syndrome | 8 |
recent advances | 8 |
radiographic findings | 8 |
healthcare system | 8 |
inhibitory concentration | 8 |
clinical evaluation | 8 |
endemic countries | 8 |
capsid protein | 8 |
genome sequencing | 8 |
two weeks | 8 |
virus challenge | 8 |
potent neutralizing | 8 |
rh phenotype | 8 |
nine patients | 8 |
light chain | 8 |
relatively high | 8 |
strains isolated | 8 |
brain tumours | 8 |
readily available | 8 |
true positive | 8 |
product utilization | 8 |
low dose | 8 |
microplate reader | 8 |
total bilirubin | 8 |
rh blood | 8 |
weeks among | 8 |
bl mice | 8 |
current study | 8 |
crystal structure | 8 |
review board | 8 |
single dose | 8 |
implementation period | 8 |
chikungunya fever | 8 |
procedure cd | 8 |
mutant rzikv | 8 |
recognition sites | 8 |
study showed | 8 |
lamp primers | 8 |
transcription factor | 8 |
group antigens | 8 |
blood utilization | 8 |
protective effect | 8 |
process improvement | 8 |
prevent zika | 8 |
blood cultures | 8 |
high correlation | 8 |
coding sequence | 8 |
cytotoxic concentration | 8 |
transfusion hemoglobin | 8 |
antiviral functional | 8 |
postnatal imaging | 8 |
diagnostic performance | 8 |
time since | 8 |
clinical management | 8 |
actin served | 8 |
high volume | 8 |
staphylococcus aureus | 8 |
molecular tweezer | 8 |
plate format | 8 |
palindromic sequences | 8 |
asymptomatic patients | 8 |
orp values | 8 |
two radiologists | 8 |
tpe procedures | 8 |
like receptor | 8 |
confidence intervals | 8 |
mouse brain | 8 |
fatty acid | 8 |
manufacturing methods | 8 |
abo blood | 8 |
contrast agents | 8 |
zikv titers | 8 |
luminex bead | 8 |
fold change | 8 |
transcription loop | 8 |
calyceal dilation | 8 |
mouth disease | 8 |
single amino | 8 |
plaque phenotype | 8 |
persistently infected | 8 |
following transfusion | 8 |
zikv diagnostic | 8 |
sequence alignment | 8 |
semen parameters | 8 |
general population | 8 |
cell antigens | 8 |
group ab | 8 |
test whether | 8 |
blood flow | 8 |
coronary artery | 8 |
prbc units | 8 |
ha antibody | 8 |
misfolded unfolded | 8 |
ferritin testing | 8 |
bone cyst | 8 |
disease onset | 8 |
upload time | 8 |
well known | 8 |
acute zikv | 8 |
pediatric trauma | 8 |
zikv vaccines | 8 |
clinical assays | 8 |
first months | 8 |
plain radiograph | 8 |
mutation frequency | 8 |
per cell | 8 |
data analysis | 8 |
emergent situations | 8 |
brain injury | 8 |
biosafety level | 8 |
represented sequence | 8 |
standard operating | 8 |
clinical care | 8 |
assay performance | 8 |
fluid signal | 8 |
appointment booking | 8 |
patients presenting | 8 |
medical director | 8 |
hematological parameters | 8 |
flavivirus infections | 8 |
tract infection | 8 |
asian strain | 8 |
give blood | 8 |
cell adherence | 8 |
findings suggest | 8 |
child abuse | 8 |
cultured cells | 8 |
focal lesions | 8 |
virus persistence | 8 |
brain damage | 8 |
aca treatment | 8 |
open reading | 8 |
done using | 8 |
plasma membrane | 8 |
recent zikv | 8 |
vertically transmitted | 8 |
immunodetection assay | 8 |
fibrinogen levels | 8 |
rational design | 8 |
new class | 7 |
rbc genotyping | 7 |
individual donation | 7 |
drug development | 7 |
abundant common | 7 |
lineage zika | 7 |
less severe | 7 |
cytometry analysis | 7 |
cell concentrates | 7 |
maximum surgical | 7 |
diagnostic testing | 7 |
controlled trial | 7 |
zikv copies | 7 |
urgent need | 7 |
future state | 7 |
inhibit zika | 7 |
internal medicine | 7 |
joint space | 7 |
transmitted via | 7 |
significantly reduces | 7 |
technical staff | 7 |
prevent transfusion | 7 |
lung disease | 7 |
isotype control | 7 |
disorder differences | 7 |
sg markers | 7 |
gestational week | 7 |
fetal disease | 7 |
george chen | 7 |
intravenous immunoglobulin | 7 |
reagent management | 7 |
log pfu | 7 |
infection using | 7 |
diagnostic approach | 7 |
mild disease | 7 |
assays perform | 7 |
donor deferrals | 7 |
fluorescence signal | 7 |
zikv immunodetection | 7 |
best practices | 7 |
diabetes mellitus | 7 |
lateral ventricles | 7 |
serial dilution | 7 |
cancer center | 7 |
south china | 7 |
current state | 7 |
plate reader | 7 |
cns involvement | 7 |
bac clone | 7 |
corresponding virus | 7 |
remote blood | 7 |
cell supernatants | 7 |
factors involved | 7 |
ct group | 7 |
hepatocellular carcinoma | 7 |
quantitative real | 7 |
fatality rate | 7 |
molecular tweezers | 7 |
potential therapeutic | 7 |
olfactory nerve | 7 |
local transmission | 7 |
emerging pathogens | 7 |
four different | 7 |
wt sequence | 7 |
lung injury | 7 |
iatrogenic blood | 7 |
exclude concomitant | 7 |
index donations | 7 |
using gamma | 7 |
seizure activity | 7 |
matched controls | 7 |
potential complications | 7 |
electronic ordering | 7 |
dmem supplemented | 7 |
acid substitution | 7 |
detection system | 7 |
adamts activity | 7 |
south american | 7 |
functional residues | 7 |
zikv infects | 7 |
virus may | 7 |
frontal cxr | 7 |
assisted ba | 7 |
mri images | 7 |
binding kinase | 7 |
clone plasmid | 7 |
month old | 7 |
venous return | 7 |
zikv multiplication | 7 |
abbott diagnostics | 7 |
transmission cycle | 7 |
abo discrepancy | 7 |
placental damage | 7 |
automatic appointment | 7 |
mr urography | 7 |
partial protection | 7 |
clinical setting | 7 |
igm igg | 7 |
reduction technology | 7 |
considered positive | 7 |
mri findings | 7 |
will require | 7 |
igg titers | 7 |
type plasmid | 7 |
fetal autopsy | 7 |
adult ag | 7 |
increased blood | 7 |
high level | 7 |
genome copy | 7 |
southeast asia | 7 |
samples showed | 7 |
rh confirmation | 7 |
dna extracted | 7 |
dara treatment | 7 |
examination showed | 7 |
taken together | 7 |
fort collins | 7 |
rh haplotypes | 7 |
zikv cases | 7 |
platelet aggregation | 7 |
imaging modalities | 7 |
total cell | 7 |
infected mouse | 7 |
outside africa | 7 |
swab samples | 7 |
cd yield | 7 |
genetic variants | 7 |
health background | 7 |
ncam antibody | 7 |
like illness | 7 |
hydrodynamic radius | 7 |
asian zikv | 7 |
hemoglobin level | 7 |
microvascular endothelial | 7 |
copy numbers | 7 |
placental cells | 7 |
transfusion hgb | 7 |
listeria monocytogenes | 7 |
study population | 7 |
new insights | 7 |
statistically significantly | 7 |
oxygen affinity | 7 |
preliminary report | 7 |
effective doses | 7 |
collected using | 7 |
supplementary material | 7 |
binding affinity | 7 |
traveller returning | 7 |
viruses doi | 7 |
human respiratory | 7 |
group received | 7 |
assessed whether | 7 |
vps scores | 7 |
liver transplant | 7 |
negative predictive | 7 |
stable patients | 7 |
virion assembly | 7 |
study evaluated | 7 |
virus impairs | 7 |
phase ii | 7 |
immunofluorescent staining | 7 |
iron stores | 7 |
clinical information | 7 |
mk cells | 7 |
related complications | 7 |
zimmer biomet | 7 |
phylogenetic trees | 7 |
ic value | 7 |
apparent diffusion | 7 |
bac approach | 7 |
molecular determinants | 7 |
synthetic dna | 7 |
will need | 7 |
specific cellular | 7 |
diffusion coefficient | 7 |
protein interaction | 7 |
clinical development | 7 |
hbv infection | 7 |
pneumatic tube | 7 |
marburg virus | 7 |
coagulation parameters | 7 |
placental blood | 7 |
transfusion protocols | 7 |
sequences identified | 7 |
sgs assembly | 7 |
bacterial artificial | 7 |
hospital customers | 7 |
kg day | 7 |
antibodies targeting | 7 |
dara interference | 7 |
htlv ii | 7 |
dna sequences | 7 |
positive rbcs | 7 |
apoptotic cell | 7 |
per day | 7 |
inhibiting zikv | 7 |
mers coronavirus | 7 |
ost complex | 7 |
wbc ul | 7 |
nonhuman primates | 7 |
cell receptors | 7 |
neonatal intensive | 7 |
infection causes | 7 |
gregg williams | 7 |
parenchymal volume | 7 |
primate model | 7 |
emerging infections | 7 |
living cells | 7 |
neural cell | 7 |
virus dna | 7 |
increased walk | 7 |
strand rna | 7 |
concomitant infections | 7 |
replication complex | 7 |
continued pressures | 7 |
tubular matrices | 7 |
type iii | 7 |
tested mabs | 7 |
may still | 7 |
among pregnant | 7 |
diagnostic samples | 7 |
birth weight | 7 |
rank test | 7 |
causes birth | 7 |
vessel wall | 7 |
three cell | 7 |
bone age | 7 |
different clr | 7 |
emd millipore | 7 |
zurich ch | 7 |
cmap amplitude | 7 |
blue arrows | 7 |
related failed | 7 |
transfusion transmission | 7 |
young children | 7 |
blood mononuclear | 7 |
mers cov | 7 |
platelet collection | 7 |
included patients | 7 |
new clinical | 7 |
lethal infection | 7 |
antiviral therapies | 7 |
years ago | 7 |
post infection | 7 |
two samples | 7 |
published literature | 7 |
viral titres | 7 |
random blood | 7 |
antibody testing | 7 |
represent standard | 7 |
growth factors | 7 |
lateral ridge | 7 |
zikv human | 7 |
arbovirus infection | 7 |
laboratory findings | 7 |
zikv env | 7 |
prediction algorithm | 7 |
medicine service | 7 |
rna detection | 7 |
transcription pcr | 7 |
procleix zikv | 7 |
host proteins | 7 |
infected patient | 7 |
arbovirus infections | 7 |
clinical specimens | 7 |
vaccine candidate | 7 |
phylogenetic tree | 7 |
months post | 7 |
comparative analysis | 7 |
human transmission | 7 |
inhibit type | 7 |
leydig cells | 7 |
six patients | 7 |
laboratory tests | 7 |
mortem imaging | 7 |
supplementary data | 7 |
murine model | 7 |
control cells | 7 |
relatively small | 7 |
patient demographics | 7 |
remains unclear | 7 |
recent epidemics | 7 |
commodity waste | 7 |
specific igg | 7 |
extracellular vesicles | 7 |
hospital based | 7 |
organ transplant | 7 |
tubing segments | 7 |
higher sensitivity | 7 |
control zikv | 7 |
conventional mri | 7 |
five years | 7 |
cmv infection | 7 |
dynamic contrast | 7 |
studies suggest | 7 |
high grade | 7 |
slice ct | 7 |
adamts deficiency | 7 |
cdna clones | 7 |
process steps | 7 |
final volume | 7 |
days using | 7 |
pulmonary sequestration | 7 |
human neurospheres | 7 |
antiviral compound | 7 |
also noted | 7 |
may serve | 7 |
meconium peritonitis | 7 |
reactive antibodies | 7 |
supplementary figures | 7 |
mark paradowski | 7 |
mycophenolic acid | 7 |
emerging zika | 7 |
cell transfusion | 7 |
hour post | 7 |
days two | 7 |
published data | 7 |
vitro transcription | 7 |
human placenta | 7 |
community hospitals | 7 |
including zikv | 7 |
serial passage | 7 |
independent variable | 7 |
brain swelling | 7 |
continuous variables | 7 |
enhanced automation | 7 |
placental macrophages | 7 |
epidemic arboviral | 7 |
novel antiviral | 7 |
placental transfer | 7 |
five mice | 7 |
transmission electron | 7 |
sylvatic transmission | 7 |
treatment stage | 7 |
data collected | 7 |
two additional | 7 |
clerical errors | 7 |
study sponsors | 7 |
icu patients | 7 |
wrist radiography | 7 |
infection damages | 7 |
concurrent epidemics | 7 |
ray imaging | 7 |
donation frequency | 7 |
small volume | 7 |
maternal immunization | 7 |
identified natural | 7 |
study group | 7 |
gt mefs | 7 |
result showed | 7 |
blunt abdominal | 7 |
rhce variants | 7 |
imaging studies | 7 |
congenital rubella | 7 |
significant effect | 7 |
cell responses | 7 |
secure texting | 7 |
study day | 7 |
jane bryant | 7 |
statistical software | 7 |
transfusion guidelines | 7 |
close proximity | 7 |
rubella virus | 7 |
george schlauder | 7 |
ediii without | 7 |
clr concentrations | 7 |
day prior | 7 |
human pathogens | 7 |
increased expression | 7 |
received ivig | 7 |
bovine viral | 7 |
molecular genotyping | 7 |
epidemic areas | 7 |
lung ultrasound | 7 |
vaccinia virus | 7 |
chikungunya viruses | 7 |
mice vaccinated | 7 |
cells zika | 7 |
abnormal risk | 7 |
unit transfusion | 7 |
stress responses | 7 |
basal ganglia | 7 |
viral polymerase | 7 |
also significantly | 7 |
significant changes | 7 |
also assessed | 7 |
acid test | 7 |
least cells | 7 |
mild symptoms | 7 |
mutagenic activity | 7 |
human stat | 7 |
clinical studies | 7 |
ns rna | 7 |
walk away | 7 |
panel cells | 7 |
medical history | 7 |
denv ediii | 7 |
may require | 7 |
may represent | 7 |
without compromising | 7 |
skeletal age | 7 |
dexamethasone withdrawal | 7 |
pcr using | 7 |
interferon receptor | 7 |
septic patients | 7 |
operations demand | 7 |
null phenotype | 7 |
maternal blood | 7 |
cfu ml | 7 |
fluorescence microscope | 7 |
one rbc | 7 |
ml penicillin | 7 |
high inhibitor | 7 |
paediatric radiologist | 7 |
patient underwent | 7 |
exchange transfusion | 7 |
using routine | 7 |
infants born | 7 |
gfp reporter | 7 |
lactate dehydrogenase | 7 |
among women | 7 |
rare blood | 7 |
recombinant type | 7 |
immune cell | 7 |
arachidonic acid | 7 |
mayaro virus | 7 |
clinical significance | 7 |
infected group | 7 |
vascular access | 7 |
immune globulin | 7 |
transfused per | 7 |
state fmri | 7 |
zikv serology | 7 |